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The objective of this study was to determine the effects of weight loss on heart rate variability (HRV) and its association with traditional cardiovascular disease risk factors in overweight and obese patients with type 2 diabetes. Forty five patients [body mass index (BMI) 35.4 Ϯ 0.7 kg/m 2 ; age 56.5 Ϯ 1.1 yr] with type 2 diabetes followed an energy-restricted diet (6 -7 MJ/day) for 16 wk. Body weight, blood pressure, glucose, insulin, insulin resistance [homeostasis model assessment index 2 (HOMA2)], glycosylated hemoglobin (HbA1c), total cholesterol, low-density lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides, resting HR, and HRV were measured before and after the intervention period. Mean reduction in body weight was 11.1 Ϯ 1.0 kg (10%), with significant reductions in blood pressure (Ϫ10%), total cholesterol (Ϫ15.9%), LDL (Ϫ17.7%), HDL (Ϫ7.5%), triglycerides (Ϫ21.2%), glucose (Ϫ23.4%), insulin (Ϫ37.6%), HOMA2 (Ϫ40.1%), and HbA1c (Ϫ14.5%) (P Յ 0.05 for all variables). There were increases in several HRV components, including total power (1,370 Ϯ 280 to 2,045 Ϯ 280 ms 2 ), low-frequency power (345 Ϯ 70 to 600 Ϯ 108 ms 2 ), SD of normal to normal intervals (SDNN; 35.0 Ϯ 2.5 to 43.0 Ϯ 2.7 s), and square root of the mean squared differences of successive normal to normal intervals (RMSSD; 23.0 Ϯ 3.5 to 32.0 Ϯ 3.1 s), and a decrease in HR (69.0 Ϯ 1.3 to 60.0 Ϯ 1.2 beats/min) (P Յ 0.03 for all variables). Changes in HR, SDNN, total power, and low-frequency power correlated with change in BMI (P Ͻ 0.05). In addition to improvements in traditional cardiovascular and metabolic risk factors, weight loss improves HRV in overweight and obese patients with type 2 diabetes. diabetic autonomic dysfunction; cardiovascular risk factors; autonomic cardiovascular control HEART RATE VARIABILITY (HRV), the variation of heart rate on time scales of seconds to hours, has been shown to reflect changes in autonomic nervous system activity. Two important frequency components of HRV are high-frequency power (HFP), which reflects efferent parasympathetic activity and which is predominant at rest, and low-frequency power (LFP), which reflects sympathetic/parasympathetic interactions and baroreceptor activity (27). The LF:HF ratio therefore reflects the balance between the sympathetic and parasympathetic nervous activity, known as sympathovagal balance. Depressed HRV has been identified as a cardiovascular risk factor and is correlated with increased mortality risk among patients with and without heart disease (3, 5) .
Diabetic autonomic neuropathy is a common and severe complication of type 2 diabetes, causing a dysregulation of autonomic control of the cardiovascular system known as cardiac autonomic neuropathy (8, 22) . Cardiac autonomic neuropathy and related conditions are characterized by accelerated reductions in HRV during disease progression compared with what would be considered a normal rate of reduction based on age, sex, and other unmodifiable factors (16, 28) . Obesity is a key risk factor for the development of type 2 diabetes, with the majority of patients with type 2 diabetes being either overweight or obese (11) . Obesity itself has been shown to alter autonomic nervous system activity and weight gain decreases HRV (6 -7, 10) . Conversely, weight loss via dieting or gastroplasty has been shown to improve cardiac autonomic function and enhance HRV via increased cardiac vagal modulation in normal, otherwise healthy, obese individuals (4, 12, 17, 19) . Such an improvement in HRV with weight loss in diabetic subjects could be an important indicator of reduced cardiovascular risk. Of concern, therefore, is the possibility that alteration of autonomic responsiveness in diabetic subjects may preclude such a beneficial effect. However, no studies to date have evaluated the effects of weight loss alone on HRV in overweight or obese patients with type 2 diabetes. This study therefore aimed to determine whether weight loss following a hypocaloric diet can improve HRV in overweight and obese adults with type 2 diabetes.
METHODS
Participants. Forty-five overweight and obese participants with type 2 diabetes were recruited via public advertisement. Participants completed a health-screening questionnaire and were not eligible to participate if they had known proteinuria, a malignancy, a history of liver, kidney, cardiovascular, respiratory or gastrointestinal disease, uncontrolled hypertension, or were pregnant, lactating, a smoker or were using insulin. All experimental procedures were approved by the Human Research Ethics Committees of the University of Adelaide and Commonwealth Scientific and Industrial Research Organisation (CSIRO). Written informed consent was obtained from all participants before commencement. The participants had a mean age of 56.5 Ϯ 1.1 yr and body mass index (BMI) of 35.4 Ϯ 0.7 kg/m 2 . Twenty-five of the subjects were taking metformin. Their baseline characteristics are presented in Table 1 .
Type 2 diabetes status. If a participant had been previously diagnosed with type 2 diabetes and was on hypoglycemic medication, diabetes status was accepted. If the participant was not on hypoglycemic medication, HBA1c was used to confirm diabetes status (Hb1Ac Ͼ 7%). If there was no recent previous HBA1c result provided, a venous blood sample was taken at screening for analysis of HbA1c. Mean diabetes duration was 6 Ϯ 5 yr.
Study design. Participants followed a 16-wk energy-restricted diet (6 -7 MJ/day) based on a prescriptive fixed menu plan with a primary goal to attain weight loss of 0.5-1.0 kg/wk. To facilitate dietary compliance, every 2 wk, participants met with a qualified dietician who provide detailed dietary instruction. Before (baseline) and after the 16-wk weight loss intervention, participants attended the clinic after an overnight fast. Height (baseline only), body weight, waist circumference, and blood pressure were measured, and electrocardiogram (ECG) recordings taken. A venous blood sample was then drawn for the measurement of glucose, insulin, lipids, and glycosylated hemoglobin (HbA1c).
Clinical and biochemical measurements. Weight was measured using calibrated weight scales (Mercury, AMZ 14, Tokyo, Japan) to the nearest 0.05 kg, with participants wearing light clothing and no footwear. Waist circumference (WC) was measured to the nearest millimeter using a standard tape measure 3 cm above the iliac crest. The average of 3 measures was recorded as the measured value. Systolic and diastolic blood pressure was measured by an automatic sphygmomanometer (DYNAMAP 8100, Criticon, Tampa, FL) with participants seated after a 5-min rest. Three readings were taken, each separated by 2 min, with the average score recorded as the measured value. Venous blood samples were collected into vacutainer tubes containing either no additives or sodium fluoride/EDTA (1 g/l) and the serum/plasma isolated by centrifugation for 10 min at 2,000 g (5°C) (Beckman GS-6R Centrifuge CA) and stored at Ϫ80°C until study completion. Serum lipids (total cholesterol, HDL cholesterol, and triglycerides) and plasma glucose were measured on a Hitachi 902 autoanalyzer (Roche Diagnostics, Indianapolis, IN) using commercial enzymatic kits (Roche Diagnostics, Basel, Switzerland). The Friedewald equation was used to calculate LDL-C levels . HbA1c was measured using high-performance liquid chromatography (IMVS, Adelaide, Australia). Insulin was measured in duplicate using Mercodia Insulin ELISA (Mercodia AB, Uppsala, Sweden). The Computerized Homeostatic Model Assessment 2 (HOMA2-IR) was used as a surrogate measure of insulin resistance based on fasting glucose and insulin concentrations (23) .
Cardiac parameters. ECG recordings were recorded supine for 10 min after an equilibration period of 5 min (data acquisition system: Powerlab Model ML880, ADInstruments, Bella Vista, Australia). ECG data were analyzed off-line using the HRV Module 1.01 for Chart 5 (ADInstruments, Bella Vista, Australia). All ECGs were recorded according to the standards of measurements, physiological interpretation, and clinical use guidelines for assessment of HRV (27). Resting heart rate (HR) was determined using the calculated average time between each of the successive R waves over the 10-min recording. This duration of recording gives good definition of frequency domain measures, and acceptable resolution of time domain measures (27). Time and frequency domain measures were calculated for HRV as previously reported (18, 24) . Time domain measures included standard deviation of normal to normal intervals (SDNN) and the square root of the mean squared differences of successive normal to normal intervals (RMSSD). Frequency domain parameters of HRV were derived using power spectrum analysis (fast Fourier transforms) with highfrequency power (HFP, defined as 0.15-0.40 Hz) and low-frequency power (LFP, defined as 0.04 -0.15 Hz) expressed in normalized units adjusting for changes in total power. Poincare plots were used to determine the normal distribution of HRV.
Statistics. Statistical analysis was performed using SPSS for Windows 15.0 (SPSS, Chicago, IL). Data were assessed for normality and a logarithmic scale was applied to the frequency domain measures of HRV for statistical analysis. The effects of weight loss on HRV and other outcomes were determined by paired t-tests. Correlational analysis was used to assess relationships between variables. Statistical significance was set at P Ͻ 0.05. All data are shown as means Ϯ SE.
RESULTS
All individuals in the analysis lost weight (range Ϫ1.44 to Ϫ26.02 kg). Overall, the mean weight loss was 11.3 Ϯ 2.1 kg (P Ͻ 0.01), which was accompanied by significant reductions in WC, blood pressure, total LDL and HDL cholesterol, triglycerides, glucose, insulin, HOMA2, and HbA1c (P Ͻ 0.05 for all variables). These results are shown in Table 1 .
Representative power spectra from one individual are shown in Fig. 1 . At week 16, HR was significantly reduced (P Ͻ 0.01). The reduction in HR correlated with %weight loss (r ϭ 0.52, P Ͻ 0.01), and the reduction in BMI (r ϭ 0.49, P Ͻ 0.01), WC (r ϭ 0.50, P Ͻ 0.01), triglycerides (r ϭ 0.35, P ϭ 0.02), insulin (r ϭ 0.31, P ϭ 0.04), and HOMA2 (rϭ0.32, P ϭ 0.04).
The HRV components total power, LFP, SDNN, and RMSSD all increased after weight loss (P Յ 0.03). HFP and LF/HF ratio did not change significantly during the intervention. The reduction in BMI was inversely correlated with the change in SDNN (r ϭ Ϫ0.30, P ϭ 0.05), total power (r ϭ Ϫ0.32, P ϭ 0.04), and LFP (rϭ Ϫ0.34, P ϭ 0.03). Changes in LFP also correlated with %change in weight (rϭ Ϫ0.34, P ϭ 0.02) and the change in WC (r ϭ Ϫ0.31, P ϭ 0.04). Although not significantly changed itself, changes in HFP correlated with change in BMI (r ϭ Ϫ0.30, P ϭ 0.05), WC (r ϭ Ϫ0.36, P ϭ 0.04), %weight loss (r ϭ Ϫ0.31, P ϭ 0.02), insulin (r ϭ Ϫ0.37, P ϭ 0.01), and insulin resistance (r ϭ Ϫ0.38, P ϭ 0.01). There was a correlation between LF/HF ratio and HOMA2 (r ϭ 0.31, P ϭ 0.04). HRV, heart rate variability; LDL, low-density lipoprotein; HDL, highdensity lipoprotein; HOMA2, homeostasis model assessment index 2; SDNN, SD of the normal to normal mean; RMSSD, the square root of the mean squared differences of successive normal to normal intervals. *P Ͻ 0.05, †P Ͻ 0.01, baseline values significantly different from values at week 16.
DISCUSSION
Many markers are used to assess cardiovascular health, and associated risk of cardiovascular adverse events, including endothelial function, pulse wave velocity, as well as the more established measures such as heart rate and blood pressure (9) . In addition, HRV is also becoming an accepted marker of cardiovascular health, and lowered HRV has been shown to be associated with increased cardiovascular risk.
There is no doubt that overweight or obesity increases cardiovascular risk and previous studies have shown that increased BMI decreases HRV (attenuates SDNN) in normal, healthy individuals, and that HRV can be improved following exercise training or with dieting in the normal population (17, 19) . Collectively, published data support a link between weight reduction and beneficial changes in the balance of sympathetic and parasympathetic activity. For example, weight loss following a hypocaloric diet has been shown to increase cardiac parasympathetic vagal tone in obese individuals (13, 20) .
Type 2 diabetes is an independent risk factor for cardiovascular disease, and type 2 diabetes also reduces HRV, presumably reflecting a decrease in cardiac autonomic control (22) . A worrying possibility, therefore, is that type 2 diabetes may attenuate or obviate the beneficial effects of weight reduction on HRV and other markers of cardiovascular health in those patients with this comorbidity. Encouragingly, the main finding of this study is that this is not so; HRV improved with modest (ϳ10 kg) weight loss in obese and overweight patients with concomitant type 2 diabetes, indicating that weight loss through dietary intervention is producing beneficial effects on a range of cardiovascular risk factors in this group.
We found a significant 12.2% reduction in resting HR, which correlated with a reduction in metabolic markers (insulin, insulin resistance, and triglycerides) and BMI. This is consistent with other studies that have also shown that weight loss can reduce HR in obese hypertensive patients (23) . The HRV markers of cardiovascular health were also improved, although some measures demonstrated this more convincingly than others. The time domain measures SDNN and RMSSD are simple measures of the mathematical variance in the heart rate. These were both highly significantly increased (by 22.6% and 37.6%, respectively) by the intervention. The increase in SDNN was significantly correlated with the reduction of BMI.
The changes in parameters derived from power spectral analysis of heart rate were also consistent, with one minor exception. Changes in all measures of HRV correlated with the change in BMI (and other measures of weight loss). Total power, LFP, and HFP were all increased substantially. Total power and LFP changes were significant at P Ͻ 0.01, but although HFP increased by over 30%, this was not statistically significant. It may be that HFP is less responsive to weight loss than the other measures, and that the weight loss in our study was not large enough to produce a statistically significant change in HFP. However, we note that other studies have attained significant improvements in HFP with a similar or lesser degree of weight loss (2, 17) . It should be noted that breathing rate and depth can affect HRV, in the HF band, and so we cannot be sure that changes in HF (or lack thereof) were not due to changes in breathing mechanics. An alternative is that our study lacked sufficient power to detect a significant change in HFP in particular, because of the high variability in this measure. A retrospective power calculation found the statistical power of the change in HFP with 45 subjects was 10%. Future studies should therefore increase the number of subjects in each trial to clearly demonstrate the significant change in HFP.
Total power and LFP are considered to represent the response to blood pressure fluctuations mediated by the baroreflex. Studies carried out using orthostatic and exercise challenges as well as pharmacological studies with beta blockers have shown the link between LFP and increase in efferent sympathetic activity, and have led to the use LFP as a marker of sympathetic activity (1, 21) . The increased LFP amplitude after weight loss in the type 2 diabetes subjects in our study is thus most likely a reflection of improved baroreceptor-dependent control of the heart, consistent with other published studies (25) .
Total cholesterol, HbA1c, and triglycerides, which are surrogate markers of global vascular health, also decreased after weight loss in our study group. These metabolic markers have previously been identified as independent markers of cardiovascular health (14) .
In conclusion, weight loss via a hypocaloric diet improved HRV in overweight and obese patients with type 2 diabetes. Since cardiac autonomic dysfunction is an indicator of adverse cardiovascular risk, the improvement in HRV after weight loss should be considered beneficial and suggests improved cardiovascular health. Importantly, we show here that overweight or obese patients with type 2 diabetes appear to have increased sympathetic activity, which can be reversed by weight loss in a way similar to that seen in nondiabetic patients (25) (26) , despite the possible confounding factors of poor autonomic control resulting from the comorbidity of type 2 diabetes. This study therefore provides further support for the clinical importance of weight loss reducing the risk of adverse cardiovascular events in overweight diabetic patients.
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